ArticleJournal of dental sciences2026
The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Immune stimulation or escape are critical factors determining the survival of malignancies, including oral squamous cell carcinoma (OSCC) and head and neck SCC (HNSCC). CD24 (CD24A in mice) is a glycoprotein anchored to cell membranes, modulating macrophages' immune responses, cell interaction, tumorigenesis, and stemness. However, its roles in the OSCC pathogenesis are still controversial. The modulation of CD24 on the oncogenicity and immunity of OSCC were investigated in this study. Materials and methods: Knockdown approaches and the establishment of stable tet-off CD24 expression cell subclones were used in cell and mouse models for phenotypic and transcriptomic analysis. Bioinformatic assessments were performed to specify the clinicopathological implications. Results: CD24 expression modulated the increase of migration and invasion and the upregulation of phosphatidylcholine/phosphatidylinositol transfer protein Sec14 like lipid binding 2 (SEC14L2) expression. The syngeneic grafts of CD24 tet-off expressing murine OSCC cell subclones exhibited modest changes of immune cell infiltration within tumors and were devoid of immune profile disruption in the recipient's neck lymph node and spleen. The shutdown of CD24 with doxycycline treatment drastically suppressed the growth of CD24 tet-off tumors. A correlation between CD24 expression and myeloid dendritic cell population was noted in murine and human OSCC tissue. Concordances in CD24 and SEC14L2 expression and oncogenic induction were noted in murine tumors. SEC14L2 was upregulated in HNSCC/OSCC tumors, and it was an unfavorable survival predictor. Conclusion: This study's elucidation of the oncogenic potential of the CD24-SEC14L2 axis may signify the therapeutic efficacy of CD24 targeting for HNSCC/OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.